Hooda, Z, Ries, S, Fabian, T, Freeman, KA, Hofstetter, WL, Hudson, J, Mehran, RJ, Rajaram, R, Rice, DC, Swisher, SG , Vaporciyan, AA, Walsh, GL, Mitchell, KG, Zaku, B, Antonoff, MB
International Regulatory Landscape Healthcare Provider Considerations Healthcare providers who prescribe or recommend BPC-157 face potential: Disciplinary action from state medical boards Medical license implications (sanctions, restrictions, suspension) Malpractice liability (insurance often excludes experimental treatments) Federal regulatory enforcement Research and Access Legitimate research pathways: Investigational New Drug (IND) application required for human research Institutional Review Board (IRB) approval required GMP standards required for research-grade materials Current access: Research peptide suppliers (variable quality) Some compounding pharmacies (legal status varies) Clinical trials (limited availability) Why This Regulatory Status Exists BPC-157's prohibition stems from: Limited clinical data Only small pilot studies published (~28 human subjects total)
Each type has unique characteristics in terms of texture, absorption, and concentration of active ingredients
PatchAid patches are free of Artificial Dyes, Casein, Corn, Colors, Dairy, Eggs, Fillers, Flavorings, Gluten, GMOs, Latex, MSG, Peanuts, Preservatives, Shellfish, Soy, Sugar, Tree Nuts, and Wheat
